Literature DB >> 31862988

ALCYONE - lighting the way for quadruplet therapy of NDMM.

David Killock1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31862988     DOI: 10.1038/s41571-019-0321-2

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.

Authors:  Maria-Victoria Mateos; Michele Cavo; Joan Blade; Meletios A Dimopoulos; Kenshi Suzuki; Andrzej Jakubowiak; Stefan Knop; Chantal Doyen; Paulo Lucio; Zsolt Nagy; Ludek Pour; Mark Cook; Sebastian Grosicki; Andre Crepaldi; Anna Marina Liberati; Philip Campbell; Tatiana Shelekhova; Sung-Soo Yoon; Genadi Iosava; Tomoaki Fujisaki; Mamta Garg; Maria Krevvata; Ying Chen; Jianping Wang; Anupa Kudva; Jon Ukropec; Susan Wroblewski; Ming Qi; Rachel Kobos; Jesus San-Miguel
Journal:  Lancet       Date:  2019-12-10       Impact factor: 79.321

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.